Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) EBITDA (2017 - 2019)

Historic EBITDA for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$1.2 million.

  • Monopar Therapeutics' EBITDA fell 3539.27% to -$1.2 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$4.2 million, marking a year-over-year decrease of 3885.63%. This contributed to the annual value of -$4.2 million for FY2019, which is 3105.32% down from last year.
  • Latest data reveals that Monopar Therapeutics reported EBITDA of -$1.2 million as of Q4 2019, which was down 3539.27% from -$744819.0 recorded in Q3 2019.
  • In the past 5 years, Monopar Therapeutics' EBITDA registered a high of -$373839.0 during Q1 2017, and its lowest value of -$14.9 million during Q3 2017.
  • Moreover, its 3-year median value for EBITDA was -$810583.0 (2018), whereas its average is -$2.0 million.
  • Over the last 5 years, Monopar Therapeutics' EBITDA had its largest YoY gain of 9569.14% in 2018, and its largest YoY loss of 13441.83% in 2018.
  • Monopar Therapeutics' EBITDA (Quarter) stood at -$713583.0 in 2017, then fell by 24.79% to -$890472.0 in 2018, then crashed by 35.39% to -$1.2 million in 2019.
  • Its EBITDA stands at -$1.2 million for Q4 2019, versus -$744819.0 for Q3 2019 and -$904633.0 for Q2 2019.